GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Anadys Pharmaceuticals, Inc. (ANDS) [hlAlert]

Rating:
Perform ANDS
3 Months Gains
down 69.60 %

Anadys Pharmaceuticals, Inc. (ANDS) rated Perform by Oppenheimer

Posted on: Thursday,  Feb 25, 2010  8:25 AM ET by Oppenheimer

Anadys Pharmaceuticals, Inc.
(NASDAQ: ANDS) rated Perform by Oppenheimer.

Anadys Pharmaceuticals, Inc., is a biopharmaceutical company committed to advancing patient care by discovering, developing and commercializing novel small molecule medicines for the treatment of viral diseases and cancer. The Company's programs focus on Toll-Like Receptor-based small molecule product candidates and direct antiviral compounds that inhibit key steps in viral proliferation. The Company has core expertise in medicinal chemistry coupled with structure-based drug design, and is developing compounds for the treatment of hepatitis C infection, hepatitis B infection and cancer.

OppenheimerFunds, Inc. has been helping investors achieve their financial goals since 1960. We are one of the nation's largest and most respected asset management companies. At OppenheimerFunds, we believe that in order for you to reach your financial goals, your investments must perform. That is why investment excellence—over the long term and across the range of our products—is our highest priority. OppenheimerFunds and its controlled affiliates offer a broad range of products and services to individuals, corporations and institutions, including mutual funds, separately managed accounts, investment management for institutions, hedge fund products, qualified retirement plans and subadvisory investment-management services.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/25/2010 8:25 AM None
None
1.90
as of 12/31/2010
1 Week   
1 Month   
3 Months   
1 YTD down  -9.95 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/14/2009 8:25 AM Buy
None
6.25 10.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy